Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

颂狄多 - NMPA Drug Approval Details

Approvals/NMPA/Deucravacitinib Tablets

Approved

化学药品

Deucravacitinib Tablets

Bristol-Myers Squibb Pharma EEIG🇨🇳 National Medical Products Administration

Approval Date: Feb 22, 2024
Approval ID: 8VIaJ4PIBbz
Company: Bristol-Myers Squibb Pharma EEIG
Type: 化学药品

Approval Details

Approval Id: 8VIaJ4PIBbz
Approval Number: 国药准字HJ20230120
Generic Name: 氘可来昔替尼片
Generic Name En: Deucravacitinib Tablets
Trade Name: 颂狄多
Drug Type: 化学药品
Dosage Form: 片剂
Strength: 6mg
Reg Date: 2024-02-22
Expired Date: 2028-10-17
Company Name: Bristol-Myers Squibb Pharma EEIG
Production Company Name: Patheon Inc
Company Detail Path: /organization/bristol-myers-squibb-pharma-eeig
Production Company Detail Path: /organization/patheon-inc

Approved

Quick Info

Agency

NMPA

Country

🇨🇳

Approval Date

Feb 22, 2024

Approval ID

8VIaJ4PIBbz

Type

化学药品

Back to NMPA Approvals